NXNN – Nexeon MedSystems Inc, Overview, Charts, Technical, And Interview

Another pink sheet company for your watchlist is NXNN, a publicly traded pink sheet stock (nxnn: otc). Nexeon is primarily a bioelectronics organization developing medical devices for cardiovascular disease treatments. The company develops technology solutions devices that include software, electronics, mechanical engineering, and pharmaceutical products.

Nxnn is also developing and commercializing NNS, a recording platform, and implantable neurostimulation. The company has many subsidiaries, including Nexeon Europe, Nexeon Medsystems Europe, Nexeon Medsystems Puerto Rico, and Pulsus Medical LLC.

The healthcare industry in 2018 reached $8.45 trillion, and it is estimated that global healthcare spending could reach $100 trillion by 2022. The healthcare industry provides an essential role in the economy of a country, determining the GDP, and exports status, capital investment, and more.

Consumers are accelerating and driving change in health care, and their goals and needs are demanding innovative health-related products, tools, and services. The preferences include the development of on-demand, digitally enabled, and virtual clinician-patient interactions.

These demands are driving patient-centric care delivery throughout the world. Their expectations are for a more holistic human health experience.

The pandemic has raised many shifts within the healthcare sector, including patient involvement in decision making, the adoption of virtual health, and many more digital innovations. The pandemic has brought about a “new normal,” and the industry advances the journey towards the future of health.

It is currently trading at 0.3002 with no change in percentage decreases or increases. The 52-week range is 0.0080 – 1.2500, and its market capitalization is 611.21K.

Looking at the chart below, it is possible nxnn is in a correction or possible downtrend, with selling pressure from 2017 driving the prices lower. Currently, Nexeon has been trading in a range from 2020. you can find a resistance area around 1.607, and a breakout of this area may signify that it is out of the range and possibly changing trend; any pullback to the resistance area would be welcome, making it the new support.

A support area estimation is at the 0.3219 area; a fall below this area could suggest more selling to the downside. A pullback to the support area would be ideal, making it a new resistance level possible to further downside.

Nxnn has displayed low volume since the beginning of the year; it would be ideal to see increased volume either by buyers or sellers. The RSI does not show an overbought or oversold condition at this time. Still, it is best to note that a stock can remain overbought or oversold for long periods, not necessarily presenting buy or sell conditions. The only real confirmation speculators look for is confirmed price action.

NXNN Reports third-quarter results for 2018

Highlights

• Manufacturing revenues are $1.9 million and decreased by 30% to $2.8 million compared to the second quarter.
• NXNN received funding under the NIH BRAIN Initiative. The Puerto Rico Science, Technology, and Research Trust gave $100,00 to support the project’s first phase.
• Entire cash equivalents and total cash reached $125,573 on September 30, 2018, and total receivables were $2.5 M.

NXNN Receives $830,000 Grant

NXNN received the grant from the National Institutes of Health, and the National Institute of Neurological Disorders and Stroke, supporting the development of cloud-based software to improve the programming for deep brain stimulation.

Will Rosellini, CEO. Commented. Nexeon is excited to begin the project, enabling the company to take a giant leap towards fully closed-loop brain stimulation. The grants are awarded to very competitive projects, and their review of the approach validates the team in their approach and technology within NXNN.

What is Deep Brain Stimulation

It is an established treatment for Parkinson’s disease, with many patients receiving inadequate symptom control. NXNN believes that the newer implantable systems provide programming flexibility.

The company intends to develop an innovative image-guided software tool to map disease-related neural signals that are more efficient and effective programming with their grant for this funded award project.

NXNN will collaborate with Neurotargeting and various other subsidiaries to create innovative software, providing it to clinicians to support device programming.

CEO, Pierre D’Haese of Neurotargeting

Our company is excited to work with Nexeon on this innovative project; deep brain stimulation is an accurate way to explore brain activity and further study neurological diseases. NXNN innovative lose loop solutions provide new possibilities in extending CranialCloud capabilities and refining neurological models.

Neurotargeting LLC

Primarily a software company focusing on new technologies, improving understanding is neurological diseases. The company has developed an IT platform CranialCloud, an indexing and modeling platform collecting neurological data from thousands of patients.

NXNN – Exploring technology and nervous system intersection

The company is a finalist in the Emerging Company Innovation Awards for 2019. The medical device company strives to explore new ways of using technology to combat diseases in a very different way, meaning that technology could deliver integrated information sources directly into the nervous system.

One of NXNN innovative creations involves using pacemakers that interface with the nervous system, changing incorrect signals to healthy signals. The patent’s suffering from Parkinson’s disease display shaking symptoms. The company’s device intercept’s that bad signal turning it into a positive one sent back directly to the nervous system.

Will Rosellini, CEO, commented about working in technology with their innovative developments.

The Intersection Of People And Technology

Currently, you will discover that many people have problems putting down a smart device or iPhone; NXNN believes that someday the information on your iPhone, which is a supercomputer, may be integrated directly into your nervous system. Already we have witnessed signs of cyborg technology in our everyday lives.

Technology People Don’t Use Anymore, preferring its replacement.

Children often experience a challenge when trying to understand the concept of money, as they often mistake the phone for cash while trying to explain the phone is only connected to the cash in the bank.

Company Challenge

Being a small publicly-traded company, NXNN often faces challenges to explain the science and innovations to the retail investing public.

Important Advancements In Technology

By the year 2027, cell phone technology characteristics and nervous systems will astound people regarding how much can be done with implantable devices. When the internet of things becomes apparent, the dramatic advances will affect how humans interact with computers.

NXNN is primarily a bioelectronics organization developing medical devices for cardiovascular disease treatments. The company develops innovative neurostimulation products designed to improve the quality of life.

The healthcare sector has an essential role in the economy of a country, determining the GDP, and exports status, capital investment, and more. The pandemic has raised several shifts within the healthcare sector, including patient involvement in decision making, the adoption of virtual health, and many more digital innovations.

Whether you are looking to the buy-side, sell-side, or want to avoid nxnn altogether. There are many reasons to spark the interests of investors and analysts. Nexeon has been trading within a tight range since the beginning of the year, and a potential breakout in either direction may create various trading opportunities. The volume has been low along with the ranging, so increased volume may be anticipated either by further news or company events, hopefully in future months to come.

2018 ended on a positive outcome for the company with entire cash equivalents, and total cash reached $125,573 on September 30, 2018, and total receivables were $2.5 M.

Nexeon received the $830,000 grant from the National Institutes of Health, and the National Institute of Neurological Disorders and Stroke, supporting the development of cloud-based software to improve the programming for deep brain stimulation. The grants received are crucial for the company’s competitive projects, and their review of the approach validates the team in their approach and technology within NXNN.

The company’s device intercept’s that bad signal turning it into a positive one sent back directly to the nervous system. NXNN believes that someday the information on your iPhone, technological advances may integrate a supercomputer directly into your nervous system. Already we have witnessed signs of cyborg technology in our everyday lives.

NXNN faces challenges as a small company to explain the science and innovations to the retail investing public.

When the internet of things becomes apparent, dramatic advances will affect how humans interact with computers and innovations created that will astound people.

If you enjoyed reading about NXNN, you might also enjoy reading about nasdaq:otel, providing wireless communication services Throughout the U.S.

Discover their company objectives and advancements in the sector. Discover buy and sell possibilities, along with fundamental ratios, for a complete view of this innovative company.

Be alerted ahead of the crowd by signing up for the newsletter, receiving up-to-date key information on all your favorite publicly traded companies, discovering essential press releases and chart information regularly.